ADICON Holdings Limited

ADICON Holdings Limited

HHKEX:9860
4.23
HKD
+0.03
(+0.71%)
2.99BMarket Cap
Apr 01Next Earn
ADICON Holdings Limited
HKEX:9860
(Hong Kong Exchange)

Recent

price

4.23

P/E

ratio

- -

div

yld

- -

ROIC.AI

2020
2021
2022
2023
2024
2025
TTM
CNY
3.79
4.67
7.43
4.78
4.04
3.69
- -
Revenue per Share
0.39
0.44
1.04
0.34
0.07
0.03
- -
Basic EPS, GAAP
0.52
0.56
0.91
0.31
0.16
0.16
- -
Free Cash Flow per Basic Share
- -
0.63
1.32
- -
- -
- -
- -
Dividend per Share
1.42
1.11
0.71
2.35
2.31
2.4
2.44
Book Value per Share
1.41
1.05
0.4
2.03
1.98
1.98
2.03
Tangible Book Value per Share
723
723
654
691
721
715
719
Basic Weighted Avg Shares
2,742
3,380
4,861
3,298
2,914
2,638
- -
Sales/Revenue/Turnover
14.9
15.81
18.6
14.62
9.31
5.96
- -
Operating Margin (%)
114
138
193
167
176
185
- -
Depreciation Expense
284
316
681
235
47
18
- -
Net Income, GAAP
19.19
22.76
16.56
24.92
31.97
56.08
- -
Effective Tax Rate (%)
10.36
9.34
14.01
7.12
1.61
0.7
- -
Profit Margin (%)
1,326
1,150
1,477
1,546
1,126
914
985
Working Capital
230
237
1,206
945
962
828
873
LT Debt
1,039
853
612
1,829
1,775
1,849
1,873
Total Equity
- -
29.66
43.74
12.37
2.57
1.33
- -
Return on Invested Capital (%)
- -
24.83
46.28
11.11
2.17
1.05
- -
Return on Capital (%)
- -
34.51
103.54
21.17
2.8
1.09
- -
Return on Common Equity (%)

Capital Structure

CNY

•

in mil. unless spec.
Jun'25
Dec'25
Jun'26
ST Debt
639
823
742
LT Borrowings
745
705
753
LT Finance Leases
102
123
121
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
709
718
715
Market Capitalization
4,306
2,728
2,588

Working Capital

CNY

•

in mil. unless spec.
Jun'25
Dec'25
Jun'26
Total Current Assets
2,931
3,011
2,869
Cash, Cash Equivalents & STI
751
176
876
Accounts Receivable, Net
1,928
1,703
1,851
Inventories
116
129
110
Total Current Liabilities
1,870
2,097
1,884
Payables & Accruals
- -
- -
- -
ST Debt
639
823
742
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
30.75%
4.2%
Free Cash Flow
- -
-10.48%
4.11%
Net Income, GAAP
- -
-15.89%
-60.77%
Sales/Revenue/Turnover
- -
2.77%
-9.46%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
2,914
2025
- -
- -
2,638
2026
- -
- -
- -

Semi-annual Earnings Per Share

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
0.07
2025
- -
- -
0.03
2026
- -
- -
- -

Semi-annual Dividends Per Share

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
- -
2025
- -
- -
- -
2026
- -
- -
- -
Business
Adicon Holdings Limited (9860.HK) is an investment holding company and one of China's top three independent clinical laboratory (ICL) service providers, operating a nationwide network of self-managed medical laboratories that deliver comprehensive diagnostic testing services to hospitals, medical examination centers, pharmaceutical companies, and contract research organizations. The company offers an extensive portfolio exceeding 4,000 testing items, including routine tests, esoteric tests, clinical immunologic testing, clinical chemistry testing, clinical molecular biology testing, and pathology testing; testing services for research and development projects; research and clinical trial services; trading of medical testing equipment; and sale of medical products. Adicon primarily serves the healthcare and biopharmaceutical sectors in mainland China through over 30 laboratories across provinces such as Zhejiang, Shandong, Anhui, Shanghai, Beijing, and others, with a network covering the national market and capabilities in high-throughput testing, data analytics, molecular biology platforms, protein technology platforms, and bioinformatics. Founded in 2004 by Ji Xun Lin and Feng Lin and headquartered at No. 208, Zhenzhong Road, West Lake District, Hangzhou, People's Republic of China, Adicon Holdings employs approximately 5,445 people and maintains principal operations in the domestic market while expanding globally. Subsidiaries include Adicon International Ltd. in Hong Kong, which supports healthcare services. The company, backed by Carlyle Group, listed on the Hong Kong Stock Exchange in 2023. In recent developments, Adicon entered a definitive agreement in November 2025 to acquire Crown Bioscience Inc. from JSR Life Sciences for $204 million, aiming to bolster its drug research and development services, translational oncology, precision medicine, and global biopharma client base of over 1,100 companies, with the transaction expected to close in mid-2026 and generate 23.1% of future revenue from outside China. Its 2025 interim results reported revenue of approximately 1.27 billion yuan, up 106% year-on-year, driven by diversified business layout, deepened AI + healthcare initiatives, and CRO revenue growth of 18%, amid strategic partnerships with major hospitals transitioning it from a testing provider to a key collaborator. These moves position Adicon to integrate preclinical CRO with clinical ICL services, enhancing its role in the global pharmaceutical R&D ecosystem.